What is it about?
This analysis looks at why including African-Americans with multiple sclerosis (MS) in clinical trials is critical to unlocking the secrets of the disease responsiveness to drugs.
Featured Image
Why is it important?
A steady and consistent fall in clinical trials' recruitment of African Americans with MS is alarming and bad for science.
Perspectives
MS is aggressive in most African American patient cohorts. The disease does not respond as well as in Caucasians. One wonders if the disease is the same.
Dr Jagannadha R Avasarala
Greenville Memorial Hospital
Read the Original
This page is a summary of: Inadequacy of Clinical Trial Designs and Data to Control for the Confounding Impact of Race/Ethnicity in Response to Treatment in Multiple Sclerosis, JAMA Neurology, August 2014, American Medical Association (AMA),
DOI: 10.1001/jamaneurol.2014.79.
You can read the full text:
Contributors
The following have contributed to this page
